Study of a new medicine for mild heart failure
Part of Heart & circulation clinical trials.
This study tests a new medicine called NT-88, which may help improve heart function in people with mild heart failure. It focuses on those with a slightly reduced pumping ability (LVEF 41-49%) and aims to see if the drug is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of heart failure, with symptoms like shortness of breath, tiredness, or swelling.
- Your heart's pumping ability (LVEF) is mildly reduced, between 41% and 49%.
- Your heart failure is stable - no major changes in symptoms or treatment for at least 3 months.
- You are not currently in the hospital or recently hospitalized for heart failure (within 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medicine called NNC0537-1482 for people with heart failure. It aims to see if the medicine helps improve symptoms and heart function.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
This study tests an experimental drug called LY3971297 to see if it can help people with chronic heart failure. It aims to find out if the drug is safe and if it improves heart function.
This trial tests an investigational medicine called CRD-4730 (taken as a pill) to see if it can improve heart function and symptoms in people with heart failure and a reduced pumping ability. It may help you feel better and slow the progression of your condition.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This study tests an experimental medicine, CDR132L, to see if it can improve heart structure and function in people with a type of heart failure where the heart muscle is thickened. If you have heart failure with normal pumping function and thickened heart walls, this trial may offer access to a new potential treatment.
Hear when a new Heart Failure With Mildly Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.